Search Results - "Gu, Yangchun"

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis by Zhang, Yixi, La, Bin, Liang, Baosheng, Gu, Yangchun

“…Objective: to evaluate the risk of treatment-related adverse events of different severity and different system with PD-1 or PD-L1 inhibitors. Methods:…”
Get full text

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study by Gu, Yangchun, Yu, Jinyu, Hu, Haifeng, Zhang, Hua, Cao, Baoshan, Liang, Li

“…Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non-small cell lung cancer (NSCLC)…”
Get full text

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer by Gu, Yangchun, He, Huiying, Wang, Mopei

“…The anti-programmed cell death receptor 1 (anti-PD-1) immunotherapy has been recommended in several treatment scenarios of metastatic urothelial cancer (UC),…”
Get full text

Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report by Gu, Yangchun, Zhu, Xiang, Cao, Baoshan, Wu, Xue, Tong, Xiaoling, Shao, Yang W, Liang, Li

“…Epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (non-SCLC) benefits from first-line treatment with first generation tyrosine kinase…”
Get full text

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China by Shi, Yuequan, Fang, Jian, Zhou, Chengzhi, Liu, Anwen, Wang, Yan, Meng, Qingwei, Ding, Cuimin, Ai, Bin, Gu, Yangchun, Yao, Yu, Sun, Hong, Guo, Hui, Zhang, Cuiying, Song, Xia, Li, Junling, Xu, Bei, Han, Zhiqiang, Song, Meijun, Tang, Tingyu, Chen, Peifeng, Lu, Hongmin, Shui, Yongjie, Lou, Guangyuan, Zhang, Dongming, Liu, Jia, Liu, Xiaoyan, Liu, Xiangning, Gao, Xiaoxing, Zhou, Qing, Chen, Minjiang, Zhao, Jing, Zhong, Wei, Xu, Yan, Wang, Mengzhao

“…Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly…”
Get full text

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique by Gu, Yangchun, Xu, Yan, Zhuang, Hongqing, Jiang, Weijuan, Zhang, Hua, Li, Xiaofeng, Liu, Yonggang, Ma, Li, Zhao, Dahai, Cheng, Yuan, Yu, Yan, Liu, Ping, Qin, Jianwen, Chen, Xueqin, Gao, Junzhen, Wang, Mengzhao, Liang, Li, Cao, Baoshan

“…Background For lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) sensitive mutation and synchronous brain metastasis (syn‐BM), when and…”
Get full text

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China by Zou, Zihua, Hao, Xuezhi, Zhang, Cuiying, Li, Haojing, Dong, Guilan, Peng, Yumei, Ma, Kewei, Guo, Ye, Shan, Li, Zhang, Yan, Liang, Li, Gu, Yangchun, Xing, Puyuan, Li, Junling

“…Background There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by…”
Get full text

Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor by Li, Qian, Sun, Tao, Zhang, Hua, Liu, Wei, Xiao, Yu, Sun, Hongqi, Yin, Wencheng, Yao, Yanhong, Gu, Yangchun, Liu, Yan'e, Yi, Fumei, Wang, Qiqi, Yu, Jinyu, Cao, Baoshan, Liang, Li

“…The literature recommends that reduced dosage of CPT-11 should be applied in patients with UGT1A1 homozygous mutations, but the impact of UGT1A1 heterozygous…”
Get full text

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy by Qian, Li, Zhaohui, Zhang, Yaping, Xu, Zhentian, Liu, Zhentao, Liu, Qiqi, Wang, Yangchun, Gu, Yan'e, Liu, Wencheng, Yin, Fumei, Yi, Yanhong, Yao, Baoshan, Cao, Li, Liang

“…Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the…”
Get full text

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study by Liang, Hongge, Song, Xia, Zhang, Yuhui, Zhang, Shucai, Li, Fang, Fang, Jian, Li, Junling, Liang, Li, Nie, Ligong, Ma, Kewei, Zhang, Liangming, Wang, Xiaohong, Xu, Junjun, Wei, Yanxia, Wang, Jinghui, Song, Qi, Tian, Guangming, Mu, Yuxin, Gu, Yangchun, Yang, Lei, Sun, Ping, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Wang, Mengzhao

“…Background Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non‐small cell lung cancer (NSCLC) harboring…”
Get full text

Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients 
Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis: 
A Single-center Retrospective Study by Yin, Wencheng, Zhang, Hua, Gu, Yangchun, Yi, Fumei, Li, Qian, Liu, Yan'e, Yao, Yanhong, Liu, Zhentao, Cao, Baoshan

“…Malignant pleural effusion is one of the common clinical manifestations of patients with lung adenocarcinoma. Patients with pleural effusion at the initial…”
Get full text

Retrospective Analysis of Risk Factors for Venous Thromboembolism in 283 Patients with Lung Cancer during Systemic Therapy by Liu, Yan'e, Gu, Yangchun, Yi, Fumei, Cao, Baoshan

“…Patients with lung cancer have high risk of developing venous thromboembolism (VTE), which has been shown to have a significant impact on mortality. This study…”
Get full text

Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer by Yi, Fumei, Gu, Yangchun, Chen, Sen, Liu, Yan'e, Yin, Wencheng, Zhang, Yu, Cao, Baoshan

“…Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), indexes of systemic inflammation, have been associated with worse survival for…”
Get full text

Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features by Xiao, Yu, Zhu, Xiang, Gu, Yangchun, Chen, Sen, Liang, Li, Cao, Baoshan

“…There are significantly interindividual variations of the expression level of nuclear factor erythroid-2-related factor 2 (Nrf2) and/or Kelch-like…”
Get full text

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors by Gu, Yangchun, Yu, JinYu, Hu, Haifeng, Zhang, Hua, Cao, Baoshan, Liang, Li

“…e21034 Background: Epidermal growth factor receptor (EGFR) exon 19 deletion (Ex19del) in non-small cell lung cancer (NSCLC) consists of many subtypes, and…”
Get full text

Dilemma and solutions of treatment delay in cancer patients during the COVID‐19 pandemic: A single‐center, prospective survey by Liu, Yan'e, Yao, Yanhong, Wang, Qiqi, Liu, Zhentao, Gu, Yangchun, Zhang, Hua, Yi, Fumei, Cao, Baoshan

“…Introduction During the COVID‐19 pandemic, the protective and medical resources were limited, while a limited number of studies have concentrated on the…”
Get full text

Different patterns of treatment‐related adverse events of programmed cell death‐1 and its ligand‐1 inhibitors in different cancer types: A meta‐analysis and systemic review of clinical trials by Gu, Yangchun, Zhang, Hua, Liu, Zexiang, Xia, Yifan, Liang, Baosheng, Liang, Li

“…Programmed cell death receptor‐1 and its ligand‐1 (PD‐1/PD‐L1) inhibitors have been applied to many cancers, but the difference of treatment‐related adverse…”
Get full text

Expression and clinical significance of CD74 and MMP-9 in colon adenocarcinomas by Ruan, Peng, Gu, Yangchun, Zhou, Huijun, Zhang, Wen, Wang, Dingxue, Liang, Jinglin, Li, Cong

“…To detect the expressions of CD74 and matrix metalloproteinase-9 (MMP-9) in colon adenocarcinomas, and to explore the relationship between the expressions and…”
Get more information

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study by Zhang, Dongming, Liu, Xiaoyan, Shen, Fangfang, Zhao, Dahai, Shi, Yuequan, Zhang, Haoran, Liu, Jia, Gao, Xiaoxing, Chen, Minjiang, Zhao, Jing, Zhong, Wei, Gao, Junzhen, He, Min, Liu, Yonggang, Yang, Xiaoling, Qin, Jianwen, Tang, Yuling, Mu, Xinlin, Gu, Yangchun, Zhang, Shucai, Chen, Xueqin, Pang, Li, Meng, Qingwei, Guo, Ye, Zhang, Yuhui, Li, Wei, Xing, Puyuan, Cheng, Yuan, Xin, Tao, Li, Qingxia, Li, Yu, Chen, Jun, Gao, Feng, Jin, Bo, Rossi, Antonio, Adachi, Hiroyuki, Guerrera, Francesco, Husain, Hatim, Xu, Yan, Wang, Mengzhao

Get full text

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort by Zou, Zihua, Gu, Yangchun, Liang, Li, Hao, Xuezhi, Fan, Chengjuan, Xin, Tao, Zhao, Songchen, Liu, Ziling, Guo, Ye, Ma, Kewei, Li, Haojing, Zhang, Cuiying, Shan, Li, Zhang, Yan, Dong, Guilan, Peng, Yumei, Shen, Fangfang, Song, Xia, Christopoulos, Petros, Wekken, Anthonie J. van der, Okuda, Katsuhiro, Ekman, Simon, Xing, Puyuan, Li, Junling

Get full text